A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 446 participants.

Also called NCT05552326

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 446 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05552326
  • EudraCT 2022-501420-20
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Belgium, Brazil, Bulgaria, Canada, Czechia, France, Greece, Hungary, India, Italy, Lithuania, Malaysia, Mexico, Netherlands, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05552326. Randomized; triple masking; primary purpose treatment. Start 2022-08-31 (actual); primary completion 2024-12-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
Condition
Severe Hypertriglyceridemia
Intervention (Drug)
Olezarsen
Intervention (Drug)
Placebo
Lead sponsor
Ionis Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05552326
Content hash
01fee9c728cd5f8267d33730e76fa41dbb1824a4aea268b2038be5c1e973a804